• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

    29.60 -0.35 (-1.17%)
    Streaming Delayed Price Updated: 11:33 AM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Assembly Biosciences, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗
    Via Stocktwits
    News headline image
    Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with Strong Growth Fundamentals ↗
    Assembly Biosciences (ASMB) exemplifies a high-growth momentum stock, meeting strict technical uptrend criteria and showing accelerating earnings and sales fundamentals. 
    Via Chartmill
    News headline image
    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with High Growth Momentum ↗
    Assembly Biosciences (ASMB) stock meets Mark Minervini's Trend Template with a perfect technical rating, 397% from lows, and accelerating 298% revenue growth. 
    Via Chartmill
    News headline image
    Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Forecasting The Future: 4 Analyst Projections For Assembly Biosciences ↗
     
    Via Benzinga
    News headline image
    Assembly Biosciences Announces Upcoming Investor Conference Participation
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
    Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
     
    Via Benzinga
    News headline image
    Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.